Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma

Completed · Phase 2

Conditions studied: Rectal Carcinoma

In brief

Determine if genotype-directed neoadjuvant chemoradiation, using information from the thymidylate synthase promoter polymorphism, result in a greater degree of tumor downstaging in high risk patients compared to historical controls.

Key facts

Study ID
NCT00682786
Run by
Washington University School of Medicine
People needed
135
Starts
2002-10-01
Expected to finish
2010-08-01
Last updated by the study team
2017-10-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.